Published in Neurology on November 04, 2008
Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet (2011) 2.34
Huntington's disease: a clinical review. Orphanet J Rare Dis (2010) 2.12
PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci Transl Med (2012) 2.07
Measures of growth in children at risk for Huntington disease. Neurology (2012) 1.59
Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet (2011) 1.48
Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci (2013) 1.47
Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet (2010) 1.38
Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev (2009) 1.37
Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease. PLoS One (2012) 1.31
Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One (2009) 1.31
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim Biophys Acta (2011) 1.16
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci (2010) 1.10
Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet (2010) 1.06
Neuroendocrine disturbances in Huntington's disease. PLoS One (2009) 1.06
PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog Neurobiol (2011) 1.00
Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease. Behav Brain Res (2009) 0.99
Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology (2009) 0.98
Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today (2014) 0.97
Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther (2014) 0.92
A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice. PLoS One (2013) 0.89
Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. PLoS One (2013) 0.89
Weight changes in subthalamic nucleus vs globus pallidus internus deep brain stimulation: results from the COMPARE Parkinson disease deep brain stimulation cohort. Neurosurgery (2011) 0.88
Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease. Eur J Hum Genet (2010) 0.86
How vital is sleep in Huntington's disease? J Neurol (2010) 0.86
Huntington's Disease and Striatal Signaling. Front Neuroanat (2011) 0.86
Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain. J Neural Transm (Vienna) (2009) 0.86
Intermediate CAG Repeats in Huntington's Disease: Analysis of COHORT. Tremor Other Hyperkinet Mov (N Y) (2012) 0.84
Therapeutic approaches to preventing cell death in Huntington disease. Prog Neurobiol (2012) 0.84
Dysfunctional mitochondrial respiration in the striatum of the Huntington's disease transgenic R6/2 mouse model. PLoS Curr (2013) 0.83
Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol (2013) 0.83
The orexin neuropeptide system: physical activity and hypothalamic function throughout the aging process. Front Syst Neurosci (2014) 0.83
Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? Int J Biol Sci (2014) 0.82
From pathways to targets: understanding the mechanisms behind polyglutamine disease. Biomed Res Int (2014) 0.81
Reduced motivation in the BACHD rat model of Huntington disease is dependent on the choice of food deprivation strategy. PLoS One (2014) 0.79
A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease. PLoS One (2015) 0.79
Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamine. J Huntingtons Dis (2014) 0.78
Neuroprotective potential of escitalopram against behavioral, mitochondrial and oxidative dysfunction induced by 3-nitropropionic acid. Ann Neurosci (2015) 0.78
A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington's Disease. J Huntingtons Dis (2016) 0.77
Combination of lycopene, quercetin and poloxamer 188 alleviates anxiety and depression in 3-nitropropionic acid-induced Huntington's disease in rats. J Intercult Ethnopharmacol (2014) 0.77
Metabolic disruption identified in the Huntington's disease transgenic sheep model. Sci Rep (2016) 0.77
Abnormal Weight and Body Mass Index in Children with Juvenile Huntington's Disease. J Huntingtons Dis (2015) 0.76
HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation. PLoS One (2015) 0.76
High Protein Diet and Huntington's Disease. PLoS One (2015) 0.76
Chromosome substitution strain assessment of a Huntington's disease modifier locus. Mamm Genome (2015) 0.76
Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease. Exp Neurol (2016) 0.75
High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function. PLoS One (2017) 0.75
Mice deficient in L-12/15 lipoxygenase show increased vulnerability to 3-nitropropionic acid neurotoxicity. Neurosci Lett (2017) 0.75
Cross-phenotype association tests uncover genes mediating nutrient response in Drosophila. BMC Genomics (2016) 0.75
White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease. PLoS One (2016) 0.75
No evidence of impaired gastric emptying in early Huntington's Disease. PLoS Curr (2011) 0.75
Progressive Impairment of Lactate-based Gluconeogenesis in the Huntington's Disease Mouse Model R6/2. PLoS Curr (2015) 0.75
Study of plasma-derived miRNAs mimic differences in Huntington's disease brain. Mov Disord (2015) 0.75
Metformin intake associates with better cognitive function in patients with Huntington's disease. PLoS One (2017) 0.75
Fat-free mass and its predictors in Huntington's disease. J Neurol (2015) 0.75
Comparison of Sirtuin 3 Levels in ALS and Huntington's Disease-Differential Effects in Human Tissue Samples vs. Transgenic Mouse Models. Front Mol Neurosci (2017) 0.75
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain (2006) 5.55
J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet (1994) 3.95
Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology (1999) 3.95
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci (1999) 3.06
Rapid identification and antimicrobial susceptibility testing reduce antibiotic use and accelerate pathogen-directed antibiotic use. J Antimicrob Chemother (2007) 2.62
Reshaping the Macintosh blade using biomechanical modelling. A prospective comparative study in patients. Anaesthesia (1997) 2.57
Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology (1999) 2.13
A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response trial. Clin Endocrinol (Oxf) (2000) 2.09
Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci (2001) 2.04
Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology (2009) 2.04
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med (1992) 2.01
Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making (1997) 1.96
A bivariate approach to meta-analysis. Stat Med (1993) 1.90
Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol (1998) 1.86
An improved approach to prepare human brains for research. J Neuropathol Exp Neurol (1995) 1.84
Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology (2010) 1.74
Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.71
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain (2002) 1.71
Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effect. Pediatrics (1989) 1.63
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol (1999) 1.62
Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat Med (1995) 1.61
G-estimation of causal effects: isolated systolic hypertension and cardiovascular death in the Framingham Heart Study. Am J Epidemiol (1998) 1.59
Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology (2001) 1.54
Bivariate random effects meta-analysis of ROC curves. Med Decis Making (2008) 1.54
High-fat diet impairs hippocampal neurogenesis in male rats. Eur J Neurol (2006) 1.53
Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. Eur J Vasc Endovasc Surg (2004) 1.51
[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab (2001) 1.50
Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol (1994) 1.50
Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol (2010) 1.43
Functional integration of cortical grafts placed in brain infarcts of rats. Ann Neurol (1993) 1.43
Effect of smoking on global cognitive function in nondemented elderly. Neurology (2004) 1.42
Incidence trends for colorectal cancer in California: implications for current screening practices. Am J Med (2000) 1.42
Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum Mol Genet (2001) 1.42
Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40
Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia (1995) 1.38
Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry (2004) 1.35
Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol (2000) 1.30
Serum inhibin B as a marker of spermatogenesis. J Clin Endocrinol Metab (1998) 1.30
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A (1999) 1.30
Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol (1997) 1.29
Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience (1999) 1.28
A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ (2011) 1.27
Perioperative blood transfusion and cancer prognosis. Different effects of blood transfusion on prognosis of colon and breast cancer patients. Cancer (1987) 1.25
Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts. Nature (1990) 1.24
Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol (1989) 1.24
Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation (1995) 1.22
Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions. Neuroscience (2005) 1.22
The value of immunohistochemistry for collagen IV expression in colorectal carcinomas. Cancer (1991) 1.22
Risk factors for Alzheimer's disease: overview of the EURODEM collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 1.21
Expression of NMDAR2D glutamate receptor subunit mRNA in neurochemically identified interneurons in the rat neostriatum, neocortex and hippocampus. Brain Res Mol Brain Res (1996) 1.21
Rheumatoid factors in rheumatoid arthritis and vasculitis. Rheumatol Int (1985) 1.21
Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab (1999) 1.19
Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet (2000) 1.17
An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol (1998) 1.17
Synaptic dysfunction in Huntington's disease: a new perspective. Cell Mol Life Sci (2005) 1.16
Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain (1999) 1.14
Spontaneous remodeling of the spinal canal after conservative management of thoracolumbar burst fractures. Spine (Phila Pa 1976) (1998) 1.14
Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J Comp Neurol (1999) 1.14
Oxidative epithelial damage produces hyperresponsiveness of human peripheral airways. Am J Respir Crit Care Med (1994) 1.14
Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. Brain Res Mol Brain Res (1997) 1.14
Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol (1992) 1.13
Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol (2009) 1.12
Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J Comp Neurol (1995) 1.12
Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol (2002) 1.12
Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res (1986) 1.11
Complications from long-term indwelling central venous catheters in hematologic patients with special reference to infection. Cancer (1989) 1.11
Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci (2001) 1.10
Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol (2001) 1.09
Proton MR spectroscopy in succinic semialdehyde dehydrogenase deficiency. Neurology (2004) 1.09
Weight loss in neurodegenerative disorders. J Neurol (2009) 1.06
Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice. Neurobiol Dis (2002) 1.06
Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. Stat Med (2000) 1.06
Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med (1999) 1.06
Serum immune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis. Ann Rheum Dis (1986) 1.06
Intravascular ultrasound predictors of restenosis after balloon angioplasty of the femoropopliteal artery. Eur J Vasc Endovasc Surg (1998) 1.06
Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex. J Comp Neurol (1998) 1.05
Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol (1999) 1.05
Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res Mol Brain Res (1999) 1.04
Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res (1988) 1.04
Influence of birth size on body composition in early adulthood: the programming factors for growth and metabolism (PROGRAM)-study. Clin Endocrinol (Oxf) (2008) 1.04
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol Dis (2006) 1.03
The influence of cytomegalovirus carrier status on lymphocyte subsets and natural immunity. Clin Exp Immunol (1987) 1.03
Effects of herpes virus carrier status on peripheral T lymphocyte subsets. Blood (1987) 1.03
Flow cytometric and morphologic studies of HNK1+ (Leu 7+) lymphocytes in relation to cytomegalovirus carrier status. Clin Exp Immunol (1988) 1.03
SCA7 mouse models show selective stabilization of mutant ataxin-7 and similar cellular responses in different neuronal cell types. Hum Mol Genet (2001) 1.02
The executioners sing a new song: killer caspases activate microglia. Cell Death Differ (2011) 1.02
Standardization of grip strength measurements. Effects on repeatability and peak force. Scand J Rehabil Med (1991) 1.02
Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis (2000) 1.02
Adenocarcinoma of the colon and rectum: a report on 624 cases. Neth J Surg (1988) 1.01
Paw-reaching, sensorimotor, and rotational behavior after brain infarction in rats. Stroke (1993) 1.00
Discontinuation of antiepileptic therapy: a prospective study in children. J Neurol Neurosurg Psychiatry (1987) 1.00